- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Patent holdings for IPC class A61K 31/513
Total number of patents in this class: 4190
10-year publication summary
|
304
|
337
|
317
|
293
|
382
|
319
|
347
|
335
|
302
|
276
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1798 |
82 |
| Gilead Sciences, Inc. | 2243 |
63 |
| Merck Sharp & Dohme LLC | 3734 |
63 |
| Corcept Therapeutics, Inc. | 372 |
56 |
| Taisho Pharmaceutical Co., Ltd. | 847 |
56 |
| Immunomedics, Inc. | 238 |
44 |
| Bristol-myers Squibb Company | 4757 |
35 |
| Takeda Pharmaceutical Company Limited | 2698 |
34 |
| The Regents of the University of California | 20868 |
32 |
| Boehringer Ingelheim International GmbH | 4488 |
32 |
| F. Hoffmann-La Roche AG | 7796 |
29 |
| Genentech, Inc. | 4123 |
29 |
| MyoKardia, Inc. | 114 |
27 |
| Novartis AG | 10174 |
25 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3295 |
25 |
| Pfizer Inc. | 3414 |
24 |
| Amgen Inc. | 4445 |
24 |
| Cipla Limited | 479 |
24 |
| Sanofi | 4323 |
22 |
| Ipsen Biopharm Limited | 370 |
21 |
| Other owners | 3443 |